Functional Vascular Disorders: Treatment with Pentoxifylline

Neirotti, Massimo; Longo, Flavia; Molaschi, Mario; Macchione, Carmine; Pernigotti, Luigi
August 1987
Angiology;Aug1987, Vol. 38 Issue 8, p575
Academic Journal
A group of 11 female patients (mean age 33.7±8 years) with a clearly proven primary Raynaud's syndrome of up to five years' duration were subjected to a two-month oral treatment with 3 × 400 mg pentoxifylline per day. The following parameters were studied without and with exposure to cold conditions: hemodynamics (finger photoplethysmography), red cell deformability (filtration test), various dotting variables (prothrombin activity, antithrombin III, plasma fi- brinogen, partial thromboplastin time, thrombin time, thrombelastogram), and clinical symptomatology. After treatment 7 of the 11 patients showed a distinct improvement of pe- ripheral blood flow and of symptoms (decrease or removal of asphyxia attacks, pain, color change) under basal conditions, as well as after exposure to cold. Red cell filtration was significantly (p < 0.05) improved, increasing by 35% under normal conditions and by 30% after exposure to cold. Positive changes were also found in respect to antithrombin III (increase) and plasma fibrinogen (decrease). The thrombelastogram was unchanged. Clinical and Instrumental improvements were probably ascribable to better microcirculatory flow due to increased red cell deformability, reduced viscosity, and decreased fibrinogen, all capable of influencing in various degrees the blood flow at the microcirculatory level.


Related Articles

  • Failure of Pentoxifylline for End-stage Peripheral Vascular Disease. Loyd, Robert G.; Prian, Gregory W.; Gomez, Henry; Laub, James; Mertz, George H. // Angiology;Apr1987, Vol. 38 Issue 4, p304 

    In this trial of pentoxifylline, 15 patients with end-stage peripheral vascular disease had symptoms severe enough to warrant operation, but surgery was contraindicated because of anatomically noncorrectable disease, serious medical problems, or refusal. Their mean age was sixty-six years. Each...

  • Continuous Infusion Treatment with Pentoxifylline in Patients with Severe Peripheral Vascular Occlusive Disease. Angelides, N. S. // Angiology;Aug1986, Vol. 37 Issue 8, p555 

    The effect of continuous i.v. infusion of pentoxifylline, administering 1 200 mg/24 hours through 15 days, was studied in 22 patients (19 m, 3 f) with arterio-graphically confirmed extensive occlusion in the femoro-popIiteal segment, associated with marked intermittent claudication and rest pain...

  • Pentoxifylline in the Treatment of Vascular Impotence--Case Reports. Allenby, Kent S.; Burris, James F.; Mroczek, William J. // Angiology;May1991, Vol. 42 Issue 5, p418 

    Vascular impotence is a common medical problem for which available therapies are limited. Three impotent patients observed in the authors' practice who were receiving pentoxifylline for treatment of claudication of the lower extremities spontaneously reported improved sexual function. A...

  • Pentoxifylline Treatment in Patients with Occlusive Peripheral Arterial Disease. Circulatory Changes and Effects on Prostaglandin Synthesis. Poggesi, Loredana; Scarti, Luca; Boddi, Maria; Masolti, Giulio; Neri Serneri, Gian Gastone // Angiology;Sep1985, Vol. 36 Issue 9, p628 

    Pentoxifylline has recently been reported to stimulate in vitro the synthesis of prostacyclin. However it is not known so far whether the drug is able to stimulate prostacyclin synthesis in man also in vivo. In the present study the effects of pentoxifylline on prostaglandin synthesis and...

  • Platelet Resistance to Prostacyclin. Enhancement of the Antiaggregatory Effect of Prostacyclin by Pentoxifylline. Manrique, R. V.; Manrique, V. // Angiology;Feb1987 Part 1, Vol. 38 Issue 2, p101 

    With regard to existence of high prostacyclin (PGI2) levels during atheromatosis and thrombus formation, resistance of platelets to prostacyclin and its analogues seems to play an important pathophysiologic key role for the clarify- big of vasoocclusive phenomena. Platelet resistance to...

  • Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication? Weismantel, David // Journal of Family Practice;Feb2001, Vol. 50 Issue 2, p181 

    This article presents a study which examined the effectiveness of cilostazol over pentoxifylline in the treatment of symptoms of intermittent claudication. The study population is composed of patients with stable moderate to severe symptoms of intermittent claudication and confirmed peripheral...

  • A Pilot Study of Pentoxifylline for the Treatment of Primary Sclerosing Cholangitis. Bharucha, Adil E.; Jorgensen, Roberta; Lichtman, S. N.; LaRusso, N. F.; Lindor, K. D. // American Journal of Gastroenterology;Sep2000, Vol. 95 Issue 9, p2338 

    OBJECTIVE: There is no effective therapy for patients with primary sclerosing cholangitis (PSC). Rats with experimental small bowel bacterial overgrowth develop hepatobiliary injury similar to PSC. The hepatobiliary injury results from peptidoglycan-polysaccharide-mediated activation of Kupffer...

  • The effect of pentoxifylline on venous flap survival. Ero&gcaron;lu, L.; Karacao&gcaron;lan, N.; Uysal, O. A. // European Journal of Plastic Surgery;Aug2001, Vol. 24 Issue 4, p169 

    An experimental study was performed to determine whether the survival area of a flap can be increased using pentoxifylline in a single-pedicled venous skin flap in the rat. Epigastric island venous skin flaps measuring 1.5×2.5 cm were constructed bilaterally. The experimental group received...

  • Studies on the Mechanisms Responsible for Inhibition of Experimental Metastasis of B16-F10 Murine Melanoma by Pentoxifylline. Gude, Rajiv P.; Binda, M. Mercedes; Presas, Hector L�pez; Klein-Szanto, Andr�s J.P.; Bonfil, R. Daniel // Journal of Biomedical Science;1999, Vol. 6 Issue 2, p133 

    Pentoxifylline (PTX), a methylxanthine derivative widely used as a hemorheological agent in the treatment of peripheral vascular disease, was studied to unveil the mechanisms responsible for its inhibitory action on B16-F10 experimental metastasis. In vitro pretreatment of B16-F10 cells with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics